𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease

✍ Scribed by Ioana C. Nitu-Whalley; Anja Griffioen; Chris Harrington; Christine A. Lee

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
32 KB
Volume
66
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Limited data are available regarding optimal treatment with desmopressin (DDAVP) or intermediate‐purity FVIII concentrates rich in VWF (CFCs) in patients with von Willebrand disease (VWD) who undergo planned surgery. We undertook a retrospective review over 10 years (1988–1997) and identified 27 patients treated with DDAVP for 35 surgical events and 38 patients who received CFCs for 68 elective surgical events. Tranexamic acid was usually added for mucosal surgery. The FVIII:C levels and the severity of surgery were used to determine the frequency and the doses of postoperative treatment. For major surgery the median pre‐ and post‐operative doses of CFCs were 54 and 43 IU/kg, respectively, and for minor surgery the median doses varied between 34 and 52 IU/kg preoperatively and between 23 and 37 IU/kg postoperatively. The effectiveness of haemostasis was excellent in 32 events (91%) treated with DDAVP and in 56 events (82%) treated with CFCs. It is concluded that patients with VWD do not carry an increased operative risk if appropriate therapy is given. Am. J. Hematol. 66:280–284, 2001. © 2001 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Acquired von Willebrand disease—hemostat
Acquired von Willebrand disease—hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion
✍ Rolf Dario Frank; Dagmar Kunz; Dieter Christian Wirtz 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

## Abstract Acquired von Willebrand disease (aVWD) is a rare bleeding disorder that mimics congenital VWD in previously healthy individuals; it is most frequently associated with monoclonal gammopathy. Hemostatic therapy of aVWD is challenging due to the extremely shortened half‐life of endogenous

Dissociation between the level of von Wi
Dissociation between the level of von Willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura
✍ Carolyn E. Snider; Jane C. Moore; Theodore E. Warkentin; Clara N. Finch; Catheri 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

## Abstract Decreased von Willebrand factor (VWF)‐cleaving protease activity (<5%) has been implicated in patients with congenital thrombotic thrombocytopenic purpura–hemolytic uremic syndrome (Upshaw‐Schulman syndrome) and associated with mutations within the __ADAMTS13__ gene. In this report, we